Hoeper MM, Bogaard HJ, Condliffe R et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol, 2013; 62 (suppl.): D42-D50.
Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects A systematic review. Eur Respir J, 2009; 34: 888-894.
Herve P, Lau E, Sitbon O et al. Criteria for diagnosis of exercise pulmonary hypertension. Eur Respir J, 2015; 46: 728-737.
Vachiery JL, Adir Y, Barbera JA et al. Pulmonary hypertension due to left heart disease. J Am Coll Cardiol, 2013; 62: D100-D108.
Simonneau G, Galiè N, Rubin LJ et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol, 2004; 43 (suppl. 1): S5-S12.
Simonneau G, Gatzoulis MA, Adatia I et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol, 2013; 62: D34-D41.
Dhillon R. The management of neonatal pulmonary hypertension. Arch Dis Child Fetal Neonatal Ed, 2012; 97: F223-F228.
Porta NF, Steinhorn RH. Pulmonary vasodilator therapy in the NICU: inhaled nitric oxide, sildenafil, and other pulmonary vasodilating agents. Clin Perinatol, 2012; 39: 149-164.
Ivy DD, Abman SH, Barst RJ et al. Pediatric pulmonary hypertension. J Am Coll Cardiol, 2013; 62: D117-D126.
Humbert M, Sitbon O, Chaouat A et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med, 2006; 173: 1023-1030.
Peacock AJ, Murphy NF, McMurray JJV et al. An epidemiological study of pulmonary arterial hypertension. Eur Respir J, 2007; 30: 104-109.
McGoon MD, Benza RL, Escribano-Subias P et al. Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol, 2013; 62 (suppl.): D51-D59.
Simonneau G, Robbins I, Beghetti M et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol, 2009; 54 (suppl.): S43-S54.
Montani D, Bergot E, Günther S et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation, 2012; 125: 2128-2137.
Savale L, Chaumais MC, Cottin V et al. Pulmonary hypertension associated with benfluorex exposure. Eur Respir J, 2012; 40: 1164-1172.
Savale L, Sattler C, Gunther S et al. Pulmonary arterial hypertension in patients treated with interferon. Eur Respir J, 2014; 44: 1627-1634.
Badesch BD, Champion HC, Gomez-Sanchez MA et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol, 2009; 54 (suppl.): S55-S56.
Vahanian A, Alfieri O, Andreotti F et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J, 2012; 33: 2451-2496.
Seeger W, Adir Y, Barberà JA et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol, 2013; 62 (suppl): D109-D116.
Hurdman J, Condliffe R, Elliot CA et al. Pulmonary hypertension in COPD: results from the ASPIRE registry. Eur Respir J, 2013; 41: 1292-1301.
Cottin V, Nunes H, Brillet PY et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J, 2005; 26: 586-593.
Escribano-Subias P, Blanco I, Lopez-Meseguer M et al. Survival in pulmonary hypertension in Spain: insights from the Spanish registry. Eur Respir J, 2012; 40: 596-603.
Pengo V, Lensing AW, Prins MH et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med, 2004; 350: 2257-2264.
Pepke-Zaba J, Delcroix M, Lang I et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation, 2011; 124: 1973-1981.
Soubrier F, Chung WK, Machado R et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol, 2013; 62 (suppl.): D13-D21.
Ma L, Roman-Campos D, Austin ED et al. A novel channelopathy in pulmonary arterial hypertension. N Engl J Med, 2013; 369: 351-361.
Eyries M, Montani D, Girerd B et al. EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nat Genet, 2014; 46: 65-69.
Eddahibi S, Chaouat A, Morrell N et al. Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. Circulation, 2003; 108: 1839-1844.
Bonderman D, Wexberg P, Martischnig AM et al. A noninvasive algorithm to exclude pre-capillary pulmonary hypertension. Eur Respir J, 2011; 37: 1096-1103.
Rich JD, Thenappan T, Freed B et al. QTc prolongation is associated with impaired right ventricular function and predicts mortality in pulmonary hypertension. Int J Cardiol, 2013; 167: 669-676.
Sun PY, Jiang X, Gomberg-Maitland M et al. Prolonged QRS duration: a new predictor of adverse outcome in idiopathic pulmonary arterial hypertension. Chest, 2012; 141: 374-380.
Olsson KM, Nickel NP, Tongers J, Hoeper MM. Atrial flutter and fibrillation in patients with pulmonary hypertension. Int J Cardiol, 2013; 167: 2300-2305.
Rich S, Dantzker DR, Ayres SM et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med, 1987; 107: 216-223.
Milne EN. Forgotten gold in diagnosing pulmonary hypertension: the plain chest radiograph. Radiographics, 2012; 32: 1085-1087.
Trip P, Nossent EJ, de Man FS et al. Severely reduced diffusion capacity in idiopathic pulmonary arterial hypertension: patient characteristics and treatment responses. Eur Respir J, 2013; 42: 1575-1585.
Sun XG, Hansen JE, Oudiz RJ, Wasserman K. Pulmonary function in primary pulmonary hypertension. J Am Coll Cardiol, 2003; 41: 1028-1035.
Hoeper MM, Pletz MW, Golpon H, Welte T. Prognostic value of blood gas analyses in patients with idiopathic pulmonary arterial hypertension. Eur Respir J, 2007; 29: 944-950.
Pellegrino R, Viegi G, Brusasco V et al. Interpretative strategies for lung function tests. Eur Respir J, 2005; 26: 948-968.
Holverda S, Bogaard HJ, Groepenhoff H et al. Cardiopulmonary exercise test characteristics in patients with chronic obstructive pulmonary disease and associated pulmonary hypertension. Respiration, 2008; 76: 160-167.
Jilwan FN, Escourrou P, Garcia G et al. High occurrence of hypoxemic sleep respiratory disorders in precapillary pulmonary hypertension and mechanisms. Chest, 2013; 143: 47-55.
Rafanan AL, Golish JA, Dinner DS et al. Nocturnal hypoxemia is common in primary pulmonary hypertension. Chest, 2001; 120: 894-899.
Rudski LG, Lai WW, Afilalo J et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr, 2010; 23: 685-713.
Lang RM, Badano LP, Mor-Avi V et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging, 2015; 16: 233-271.
Foale R, Nihoyannopoulos P, McKenna W et al. Echocardiographic measurement of the normal adult right ventricle. Br Heart J, 1986; 56: 33-44.
Hachulla E, Gressin V, Guillevin L et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum, 2005; 52: 3792-3800.
Tunariu N, Gibbs SJR, Win Z et al. Ventilation-perfusion scintigraphy Is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med, 2007; 48: 680-684.
Meng JJ, Zhang LJ, Wang Q et al. A comparison of ventilation/perfusion single photon emission CT and CT pulmonary angiography for diagnosis of pulmonary embolism. Zhonghua Jie He He Hu Xi Za Zhi, 2013; 36: 177-181.
Rajaram S, Swift AJ, Telfer A et al. 3D contrast-enhanced lung perfusion MRI is an effective screening tool for chronic thromboembolic pulmonary hypertension: results from the ASPIRE Registry. Thorax, 2013; 68: 677-678.
Rajaram S, Swift AJ, Condliffe R et al. CT features of pulmonary arterial hypertension and its major subtypes: a systematic CT evaluation of 292 patients from the ASPIRE Registry. Thorax, 2015; 70: 382-387.
Shen Y, Wan C, Tian P et al. CT-base pulmonary artery measurement in the detection of pulmonary hypertension: a meta-analysis and systematic review. Medicine (Baltimore), 2014; 93: e256.
Tan RT, Kuzo R, Goodman LR et al. Utility of CT scan evaluation for predicting pulmonary hypertension in patients with parenchymal lung disease. Chest, 1998; 113: 1250-1256.
Resten A, Maitre S, Humbert M et al. Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease. Am J Roentgenol, 2004; 183: 65-70.
Dartevelle P, Fadel E, Mussot S et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J, 2004; 23: 637-648.
Reichelt A, Hoeper MM, Galanski M, Keberle M. Chronic thromboembolic pulmonary hypertension: evaluation with 64-detector row CT versus digital substraction angiography. Eur J Radiol, 2008; 71: 49-54.
Fedullo PF, Auger WR, Kerr KM, Rubin LJ. Chronic thromboembolic pulmonary hypertension. N Engl J Med, 2001; 345: 1465-1472.
Fukui S, Ogo T, Morita Y et al. Right ventricular reverse remodelling after balloon pulmonary angioplasty. Eur Respir J, 2014; 43: 1394-1402.
Castaner E, Alguersuari A, Andreu M et al. Imaging findings in pulmonary vasculitis. Semin Ultrasound CT MR, 2012; 33: 567-579.
Nawaz A, Litt HI, Stavropoulos SW et al. Digital subtraction pulmonary arteriography versus multidetector CT in the detection of pulmonary arteriovenous malformations. J Vasc Interv Radiol, 2008; 19: 1582-1588.
Peacock AJ, Vonk Noordegraaf A. Cardiac magnetic resonance imaging in pulmonary arterial hypertension. Eur Respir Rev, 2013; 22: 526-534.
Swift AJ, Rajaram S, Condliffe R et al. Diagnostic accuracy of cardiovascular magnetic resonance imaging of right ventricular morphology and function in the assessment of suspected pulmonary hypertension results from the ASPIRE registry. J Cardiovasc Magn Reson, 2012; 14: 40-50.
Swift AJ, Rajaram S, Hurdman J et al. Noninvasive estimation of PA pressure, flow, and resistance with CMR imaging: derivation and prospective validation study from the ASPIRE registry. JACC Cardiovasc Imaging, 2013; 6: 1036-1047.
Ley S, Kauczor HU, Heussel CP et al. Value of contrast-enhanced MR angiography and helical CT angiography in chronic thromboembolic pulmonary hypertension. Eur Radiol, 2003; 13: 2365-2371.
van Wolferen SA, Marcus JT, Boonstra A et al. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J, 2007; 28: 1250-1257.
Peacock AJ, Crawley S, McLure L et al. Changes in right ventricular function measured by cardiac magnetic resonance imaging in patients receiving pulmonary arterial hypertension-targeted therapy: the EURO-MR Study. Circ Cardiovasc Imaging, 2014; 7: 107-114.
van de Veerdonk MC, Kind T, Marcus JT et al. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol, 2011; 58: 2511-2519.
Albrecht T, Blomley MJ, Cosgrove DO et al. Non-invasive diagnosis of hepatic cirrhosis by transit-time analysis of an ultrasound contrast agent. Lancet, 1999; 353: 1579-1583.
Naeije R. Hepatopulmonary syndrome and portopulmonary hypertension. Swiss Med Wkly, 2003; 133: 163-169.
Hoeper MM, Lee SH, Voswinckel R et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol, 2006; 48: 2546-2552.
Kovacs G, Avian A, Pienn M et al. Reading pulmonary vascular pressure tracings. How to handle the problems of zero leveling and respiratory swings. Am J Respir Crit Care Med, 2014; 190: 252-257.
Hoeper MM, Maier R, Tongers J et al. Determination of cardiac output by the Fick method, thermodilution, and acetylene rebreathing in pulmonary hypertension. Am J Respir Crit Care Med, 1999; 160: 535-541.
Frost AE, Farber HW, Barst RJ et al. Demographics and outcomes of patients diagnosed with pulmonary hypertension with pulmonary capillary wedge pressures 16 to 18 mm Hg: insights from the REVEAL Registry. Chest, 2013; 143: 185-195.
Abraham WT, Adamson PB, Bourge RC et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet, 2011; 377: 658-666.
Prasad A, Hastings JL, Shibata S et al. Characterization of static and dynamic left ventricular diastolic function in patients with heart failure with a preserved ejection fraction. Circ Heart Fail, 2010; 3: 617-626.
Fujimoto N, Borlaug BA, Lewis GD et al. Hemodynamic responses to rapid saline loading: the impact of age, sex, and heart failure. Circulation, 2013; 127: 55-62.
Fox BD, Shimony A, Langleben D et al. High prevalence of occult left heart disease in scleroderma-pulmonary hypertension. Eur Respir J, 2013; 42: 1083-1091.
Robbins IM, Hemnes AR, Pugh ME et al. High prevalence of occult pulmonary venous hypertension revealed by fluid challenge in pulmonary hypertension. Circ Heart Fail, 2014; 7: 116-122.
Borlaug BA, Nishimura RA, Sorajja P et al. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail, 2010; 3: 588-595.
Hager WD, Collins I, Tate JP et al. Exercise during cardiac catheterization distinguishes between pulmonary and left ventricular causes of dyspnea in systemic sclerosis patients. Clin Respir J, 2013; 7: 227-236.
Halpern SD, Taichman DB. Misclassification of pulmonary hypertension due to reliance on pulmonary capillary wedge pressure rather than left ventricular enddiastolic pressure. Chest, 2009; 136: 37-43.
Naeije R, Vachiery JL, Yerly P, Vanderpool R. The transpulmonary pressure gradient for the diagnosis of pulmonary vascular disease. Eur Respir J, 2013; 41: 217-223.
Provencher S, Herve P, Sitbon O et al. Changes in exercise haemodynamics during treatment in pulmonary arterial hypertension. Eur Respir J, 2008; 32: 393-398.
Tedford RJ, Beaty CA, Mathai SC et al. Prognostic value of the pre-transplant diastolic pulmonary artery pressure-to-pulmonary capillary wedge pressure gradient in cardiac transplant recipients with pulmonary hypertension. J Heart Lung Transplant, 2014; 33: 289-297.
Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension [see comments]. N Engl J Med, 1992; 327: 76-81.
Sitbon O, Humbert M, Jaïs X et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation, 2005; 111: 3105-3111.
Barst R, McGoon M, Torbicki A et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol, 2004; 43(suppl. 1): S40-S47.
Morgan JM, McCormack DG, Griffiths MJ et al. Adenosine as a vasodilator in primary pulmonary hypertension. Circulation 1991;84:1145-1149.
Nootens M, Schrader B, Kaufmann E et al. Comparative acute effects of adenosine and prostacyclin in primary pulmonary hypertension. Chest, 1995; 107: 54-57.
Hoeper MM, Olschewski H, Ghofrani HA et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. J Am Coll Cardiol, 2000; 35: 176-182.
Opitz CF, Wensel R, Bettmann M et al. Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation. Eur Heart J, 2003; 24: 356-365.
Kim NH, Delcroix M, Jenkins DP et al. Chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol, 2013; 62: D92-D99.
Montani D, Price LC, Dorfmuller P et al. Pulmonary veno-occlusive disease. Eur Respir J, 2009; 33: 189-200.
He J, Fang W, Lv B et al. Diagnosis of chronic thromboembolic pulmonary hypertension: comparison of ventilation/perfusion scanning and multidetector computed tomography pulmonary angiography with pulmonary angiography. Nucl Med Commun, 2012; 33: 459-463.
Cottin V, Le Pavec J, Prevot G et al. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J, 2010; 35: 105-111.
Taichman DB, McGoon MD, Harhay MO et al. Wide variation in clinicians' assessment of New York Heart Association/World Health Organization functional class in patients with pulmonary arterial hypertension. Mayo Clin Proc, 2009; 84: 586-592.
Sitbon O, Humbert M, Nunes H et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol, 2002; 40: 780-788.
Nickel N, Golpon H, Greer M et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J, 2012; 39: 589-596.
Barst RJ, Chung L, Zamanian RT et al. Functional class improvement and 3-year survival outcomes in patients with pulmonary arterial hypertension in the REVEAL Registry. Chest, 2013; 144: 160-168.
Benza RL, Miller DP, Gomberg-Maitland M et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation, 2010; 122: 164-172.
McLaughlin VV, Sitbon O, Badesch DB et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J, 2005; 25: 244-249.
Sachdev A, Villarraga HR, Frantz RP et al. Right ventricular strain for prediction of survival in patients with pulmonary arterial hypertension. Chest, 2011; 139: 1299-1309.
Raymond RJ, Hinderliter AL, Willis PW et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol, 2002; 39: 1214-1219.
Bustamante-Labarta M, Perrone S, De La Fuente RL et al. Right atrial size and tricuspid regurgitation severity predict mortality or transplantation in primary pulmonary hypertension. J Am Soc Echocardiogr, 2002; 15: 1160-1164.
Forfia PR, Fisher MR, Mathai SC et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med, 2006; 174: 1034-1041.
Thenappan T, Shah SJ, Rich S et al. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J, 2010; 35: 1079-1087.
Wensel R, Opitz CF, Anker SD et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation, 2002; 106: 319-324.
McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation, 2002; 106: 1477-1482.
Fine NM, Chen L, Bastiansen PM et al. Outcome prediction by quantitative right ventricular function assessment in 575 subjects evaluated for pulmonary hypertension. Circ Cardiovasc Imaging, 2013; 6: 711-721.
Shimada YJ, Shiota M, Siegel RJ, Shiota T. Accuracy of right ventricular volumes and function determined by three-dimensional echocardiography in comparison with magnetic resonance imaging: a meta-analysis study. J Am Soc Echocardiogr, 2010; 23: 943-953.
Smith BC, Dobson G, Dawson D et al. Three-dimensional speckle tracking of the right ventricle: toward optimal quantification of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol, 2014; 64: 41-51.
Grunig E, Tiede H, Enyimayew EO et al. Assessment and prognostic relevance of right ventricular contractile reserve in patients with severe pulmonary hypertension. Circulation, 2013; 128: 2005-2015.
Swift AJ, Rajaram S, Marshall H et al. Black blood MRI has diagnostic andprognostic value in the assessment of patients with pulmonary hypertension. Eur Radiol, 2012; 22: 695-702.
Swift AJ, Rajaram S, Campbell MJ et al. Prognostic value of cardiovascular magnetic resonance imaging measurements corrected for age and sex in idiopathic pulmonary arterial hypertension. Circ Cardiovasc Imaging, 2014; 7: 100-106.
Sitbon O, McLaughlin VV, Badesch DB et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax, 2005; 60: 1025-1030.
Rich JD, Archer SL, Rich S. Noninvasive cardiac output measurements in patients with pulmonary hypertension. Eur Respir J, 2013; 42: 125-133.
Savarese G, Paolillo S, Costanzo P et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension?: a meta-analysis of 22 randomized trials. J Am Coll Cardiol, 2012; 60: 1192-1201.
Gabler NB, French B, Strom BL et al. Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. Circulation, 2012; 126: 349-356.
Fritz JS, Blair C, Oudiz RJ et al. Baseline and follow-up 6-min walk distance and brain natriuretic peptide predict 2-year mortality in pulmonary arterial hypertension. Chest, 2013; 143: 315-323.
Paciocco G, Martinez F, Bossone E et al. Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. Eur Respir J, 2001; 17: 647-652.
Provencher S, Chemla D, Herve P et al. Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension. Eur Respir J, 2006; 27: 114-120.
Sun XG, Hansen JE, Oudiz RJ, Wasserman K. Exercise pathophysiology in patients with primary pulmonary hypertension. Circulation, 2001; 104: 429-435.
Wensel R, Francis DP, Meyer FJ et al. Incremental prognostic value of cardiopulmonary exercise testing and resting haemodynamics in pulmonary arterial hypertension. Int J Cardiol, 2013; 167: 1193-1198.
Blumberg FC, Arzt M, Lange T et al. Impact of right ventricular reserve on exercise capacity and survival in patients with pulmonary hypertension. Eur J Heart Fail, 2013; 15: 771-775.
Diller GP, Dimopoulos K, Okonko D et al. Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication. Circulation, 2005; 112: 828-835.
Arena R, Lavie CJ, Milani RV et al. Cardiopulmonary exercise testing in patients with pulmonary arterial hypertension: an evidence-based review. J Heart Lung Transplant, 2010; 29: 159-173.
Pullamsetti S, Kiss L, Ghofrani HA et al. Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension. FASEB J, 2005; 19: 1175-1177.
Kielstein JT, Bode-Boger SM, Hesse G et al. Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol, 2005; 25: 1414-1418.
Kielstein JT, Impraim B, Simmel S et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation, 2004; 109: 172-177.
Kawut SM, Horn EM, Berekashvili KK et al. von Willebrand factor independently predicts long-term survival in patients with pulmonary arterial hypertension. Chest, 2005; 128: 2355-2362.
Kumpers P, Nickel N, Lukasz A et al. Circulating angiopoietins in idiopathic pulmonary arterial hypertension. Eur Heart J, 2010; 31: 2291-2300.
Rubens C, Ewert R, Halank M et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest, 2001; 120: 1562-1569.
Quarck R, Nawrot T, Meyns B, Delcroix M. C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension. J Am Coll Cardiol, 2009; 53: 1211-1218.
Balabanian K, Foussat A, Dorfmuller P et al. CX(3)C chemokine fractalkine in pulmonary arterial hypertension. Am J Respir Crit Care Med, 2002; 165: 1419-1425.
Dorfmuller P, Zarka V, Durand-Gasselin I et al. Chemokine RANTES in severe pulmonary arterial hypertension. Am J Respir Crit Care Med, 2002; 165: 534-539.
Humbert M, Monti G, Brenot F et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med, 1995; 151: 1628-1631.
Nagaya N, Nishikimi T, Uematsu M et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation, 2000; 102: 865-870.
Leuchte HH, El NM, Tuerpe JC et al. N-terminal pro-brain natriuretic peptide and renal insufficiency as predictors of mortality in pulmonary hypertension. Chest, 2007; 131: 402-409.
Fijalkowska A, Kurzyna M, Torbicki A et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest, 2006; 129: 1313-1321.
Torbicki A, Kurzyna M, Kuca P et al. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation, 2003; 108: 844-848.
Nickel N, Kempf T, Tapken H et al. Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med, 2008; 178: 534-541.
Nagaya N, Uematsu M, Satoh T et al. Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension. Am J Respir Crit Care Med, 1999; 160: 487-492.
Lorenzen JM, Nickel N, Kramer R et al. Osteopontin in patients with idiopathic pulmonary hypertension. Chest, 2011; 139: 1010-1017.
Warwick G, Thomas PS, Yates DH. Biomarkers in pulmonary hypertension. Eur Respir J, 2008; 32: 503-512.
Hoeper MM, Markevych I, Spiekerkoetter E et al. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J, 2005; 26: 858-863.
McLaughlin VV, Gaine SP, Howard LS et al. Treatment goals of pulmonary hypertension. J Am Coll Cardiol, 2013; 62 (suppl.): D73-D81.
Galiè N, Manes A, Negro L et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J, 2009; 30: 394-403.
Bai Y, Sun L, Hu S, Wei Y. Combination therapy in pulmonary arterial hypertension: a meta-analysis. Cardiology, 2011; 120: 157-165.
Galiè N, Simonneau G. The Fifth World Symposium on Pulmonary Arterial Hypertension. J Am Coll Cardiol, 2013; 62 (suppl.): D1-D3.
Galiè N, Corris P, Frost A et al. Updated treatment algorithm of pulmonary hypertension. J Am Coll Cardiol, 2013; 62 (suppl.): D60-D72.
Löwe B, Gräfe K, Ufer C et al. Anxiety and depression in patients with pulmonary hypertension. Psychosom Med, 2004; 66: 831-836.
Galiè N, Hoeper M, Humbert M et al. Guidelines on diagnosis and treatment of pulmonary hypertension: the Task Force on Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology and of the European Respiratory Society. Eur Heart J, 2009; 30: 2493-2537.
Mereles D, Ehlken N, Kreuscher S et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation, 2006; 114: 1482-1489.
de Man FS, Handoko ML, Groepenhoff H et al. Effects of exercise training in patients with idiopathic pulmonary arterial hypertension. Eur Respir J, 2009; 34: 669-675.
Grunig E, Ehlken N, Ghofrani A et al. Effect of exercise and respiratory training on clinical progression and survival in patients with severe chronic pulmonary hypertension. Respiration, 2011; 81: 394-401.
Grunig E, Maier F, Ehlken N et al. Exercise training in pulmonary arterial hypertension associated with connective tissue diseases. Arthritis Res Ther, 2012; 14: R148.
Grunig E, Lichtblau M, Ehlken N et al. Safety and efficacy of exercise training in various forms of pulmonary hypertension. Eur Respir J, 2012; 40: 84-92.
Becker-Grunig T, Klose H, Ehlken N et al. Efficacy of exercise training in pulmonary arterial hypertension associated with congenital heart disease. Int J Cardiol, 2013; 168: 375-381.
Weinstein AA, Chin LMK, Keyser RE et al. Effect of aerobic exercise training on fatigue and physical activity in patients with pulmonary arterial hypertension. Respir Med, 2013; 107: 778-784.
Chan L, Chin LM, Kennedy M et al. Benefits of intensive treadmill exercise training on cardiorespiratory function and quality of life in patients with pulmonary hypertension. Chest, 2013; 143: 333-343.
Jaïs X, Olsson KM, Barbera JA et al. Pregnancy outcomes in pulmonary arterial hypertension in the modern management era. Eur Respir J, 2012; 40: 881-885.
Duarte AG, Thomas S, Safdar Z et al. Management of pulmonary arterial hypertension during pregnancy: a retrospective, multicenter experience. Chest, 2013; 143: 1330-1336.
Thorne S, Nelson-Piercy C, MacGregor AJ et al. Pregnancy and contraception in heart disease and pulmonary arterial hypertension. J Fam Plann Reprod Health Care, 2006; 32: 75-81.
Bendayan D, Hod M, Oron G et al. Pregnancy outcome in patients with pulmonary arterial hypertension receiving prostacyclin therapy. Obstet Gynecol, 2005; 106: 1206-1210.
Bonnin M, Mercier FJ, Sitbon O et al. Severe pulmonary hypertension during pregnancy: mode of delivery and anesthetic management of 15 consecutive cases. Anesthesiology, 2005; 102: 1133-1137.
Meyer S, McLaughlin VV, Seyfarth HJ et al. Outcomes of noncardiac, nonobstetric surgery in patients with PAH: an international prospective survey. Eur Respir J, 2013; 41: 1302-1307.
Olofsson C, Bremme K, Forssell G, Ohqvist G. Cesarean section under epidural ropivacaine 0.75% in a parturient with severe pulmonary hypertension. Acta Anaesthesiol Scand, 2001; 45: 258-260.
Raines DE, Liberthson RR, Murray JR. Anesthetic management and outcome following noncardiac surgery in nonparturients with Eisenmenger's physiology. J Clin Anesth, 1996; 8: 341-347.
Guillevin L, Armstrong I, Aldrighetti R et al. Understanding the impact of pulmonary arterial hypertension on patients' and carers' lives. Eur Respir Rev, 2013; 22: 535-542.
Weitzenblum E, Sautegeau A, Ehrhart M et al. Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis, 1985; 131: 493-498.
Frydman N, Steffann J, Girerd B et al. Pre-implantation genetic diagnosis in pulmonary arterial hypertension due to BMPR2 mutation. Eur Respir J, 2012; 39: 1534-1535.
Fuster V, Steele PM, Edwards WD et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation, 1984; 70: 580-587.
Herve P, Humbert M, Sitbon O et al. Pathobiology of pulmonary hypertension: the role of platelets and thrombosis. Clin Chest Med, 2001; 22: 451-458.
Hoeper MM, Sosada M, Fabel H. Plasma coagulation profiles in patients with severe primary pulmonary hypertension. Eur Respir J, 1998; 12: 1446-1449.
Huber K, Beckmann R, Frank H et al. Fibrinogen, t-PA, and PAI-1 plasma levels in patients with pulmonary hypertension. Am J Respir Crit Care Med, 1994; 150: 929-933.
Olsson KM, Delcroix M, Ghofrani HA et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation, 2014; 129: 57-65.
Galiè N, Delcroix M, Ghofrani A et al. Anticoagulant therapy does not influence long-term outcomes in patients with pulmonary arterial hypertension (PAH): insights from the randomised controlled SERAPHIN trial of macitentan. Eur Heart J, 2014; 35: 10.
Preston RJ, Roberts KE, Miller DP et al. Effect of warfarin treatment on survival of patients with pulmonary arterial hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL). Am J Respir Crit Care Med, 2014; 189: A2464.
Cohn JN. Optimal diuretic therapy for heart failure. Am J Med, 2001; 111: 577.
Sandoval J, Aguirre JS, Pulido T et al. Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. Am J Respir Crit Care Med, 2001; 164: 1682-1687.
Rich S, Seidlitz M, Dodin E et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest, 1998; 114: 787-792.
Ruiter G, Lankhorst S, Boonstra A et al. Iron deficiency is common in idiopathic pulmonary arterial hypertension. Eur Respir J, 2011; 37: 1386-1391.
Ruiter G, Lanser IJ, de Man FS et al. Iron deficiency in systemic sclerosis patients with and without pulmonary hypertension. Rheumatology (Oxford), 2014; 53: 285-292.
Broberg CS, Bax BE, Okonko DO et al. Blood viscosity and its relationship to iron deficiency, symptoms, and exercise capacity in adults with cyanotic congenital heart disease. J Am Coll Cardiol, 2006; 48: 356-365.
Rhodes CJ, Howard LS, Busbridge M et al. Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension clinical prevalence, outcomes, and mechanistic insights. J Am Coll Cardiol, 2011; 58: 300-309.
Van De Bruaene A, Delcroix M et al. Iron deficiency is associated with adverse outcome in Eisenmenger patients. Eur Heart J, 2011; 32: 2790-2799.
Viethen T, Gerhardt F, Dumitrescu D et al. Ferric carboxymaltose improves exercise capacity and quality of life in patients with pulmonary arterial hypertension and iron deficiency: a pilot study. Int J Cardiol, 2014; 175: 233-239.
Galiè N, Ussia G, Passarelli P et al. Role of pharmacologic tests in the treatment of primary pulmonary hypertension. Am J Cardiol, 1995; 75: 55A-62A.
Mukerjee D, St George D, Coleiro B et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis, 2003; 62: 1088-1093.
Montani D, Savale L, Natali D et al. Long-term response to calcium-channel blockers in nonidiopathic pulmonary arterial hypertension. Eur Heart J, 2010; 31: 1898-1907.
Giaid A, Yanagisawa M, Langleben D et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med, 1993; 328: 1732-1739.
Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med, 1991; 114: 464-469.
Galiè N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res, 2004; 61: 227-237.
Galiè N, Badesch BD, Oudiz R et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol, 2005; 46: 529-535.
Galiè N, Olschewski H, Oudiz RJ et al. Ambrisentan for the treatment of pulmonary arterial hypertension. Results of the ambrisentan in pulmonary arterial hypertension, randomized, doubleblind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation, 2008; 117: 3010-3019.
McGoon M, Frost A, Oudiz R et al. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest, 2009; 135: 122-129.
Channick RN, Simonneau G, Sitbon O et al. Effects of the dual endothelinreceptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet, 2001; 358: 1119-1123.
Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med, 2002; 346: 896-903.
Humbert M, Barst RJ, Robbins IM et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J, 2004; 24: 353-359.
Galiè N, Rubin LJ, Hoeper M et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomized controlled trial. Lancet, 2008; 371: 2093-2100.
Galiè N, Beghetti M, Gatzoulis MA et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation, 2006; 114: 48-54.
Pulido T, Adzerikho I, Channick RN, Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med, 2013; 369: 809-818.
Wharton J, Strange JW, Moller GMO et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med, 2005; 172: 105-113.
Tantini B, Manes A, Fiumana E et al. Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Res Cardiol, 2005; 100: 131-138.
Ghofrani HA, Voswinckel R, Reichenberger F et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol, 2004; 44: 1488-1496.
Galiè N, Ghofrani HA, Torbicki A et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med, 2005; 353: 2148-2157.
Sastry BKS, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol, 2004; 43: 1149-1153.
Iversen K, Jensen AS, Jensen TV et al. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Eur Heart J, 2010; 31: 1124-1131.
Singh T, Rohit M, Grover A et al. A randomized, placebocontrolled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J, 2006; 151: 851.e1-851. e5.
Simonneau G, Rubin L, Galiè N et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension. Ann Intern Med, 2008; 149: 521-530.
Vachiery JL, Huez S, Gillies H et al. Safety, tolerability and pharmacokinetics of an intravenous bolus of sildenafil in patients with pulmonary arterial hypertension. Br J Clin Pharmacol, 2011; 71: 289-292.
Galiè N, Brundage BH, Ghofrani HA et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation, 2009; 119: 2894-2903.
Jing ZC, Yu ZX, Shen JY et al. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med, 2011; 183: 1723-1729.
Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med, 1995; 333: 214-221.
Ghofrani HA, Galiè N, Grimminger F et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med, 2013; 369: 330-340.
Galiè N, Muller K, Scalise AV, Grunig E. PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in PAH. Eur Respir J, 2015; 45: 1314-1322.
Jones DA, Benjamin CW, Linseman DA. Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades. Mol Pharmacol, 1995; 48: 890-896.
Galiè N, Manes A, Branzi A. Prostanoids for pulmonary arterial hypertension. Am J Respir Med, 2003; 2: 123-137.
Galiè N, Humbert M, Vachiery JL et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomised, double-blind placebocontrolled trial. J Am Coll Cardiol, 2002; 39: 1496-1502.
Barst RJ, McGoon M, McLaughlin VV et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol, 2003; 41: 2119-2125.
Rubin LJ, Mendoza J, Hood M et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med, 1990; 112: 485-491.
Barst RJ, Rubin LJ, Long WA et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension [see comments]. N Engl J Med, 1996; 334: 296-302.
Badesch DB, Tapson VF, McGoon MD et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial [see comments]. Ann Intern Med, 2000; 132: 425-434.
Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation, 1999; 99: 1858-1865.
Krowka MJ, Frantz RP, McGoon MD et al. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology, 1999; 30: 641-648.
Nunes H, Humbert M, Sitbon O et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med, 2003; 167: 1433-1439.
Cabrol S, Souza R, Jaïs X et al. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant, 2007; 26: 357-362.
Doran AK, Ivy DD, Barst RJ et al. Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension. Int J Clin Pract Suppl, 2008; 160: 5-9.
Sitbon O, Delcroix M, Bergot E et al. EPITOME-2: an open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension. Am Heart J, 2014; 167: 210-217.
Olschewski H, Simonneau G, Galiè N et al. Inhaled iloprost in severe pulmonary hypertension. N Engl J Med, 2002; 347: 322-329.
McLaughlin VV, Oudiz RJ, Frost A et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med, 2006; 174: 1257-1263.
Hoeper M, Leuchte H, Halank M et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J, 2006; 4: 691-694.
Higenbottam T, Butt AY, McMahon A et al. Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart, 1998; 80: 151-155.
Simonneau G, Barst RJ, Galiè N et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. A double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med, 2002; 165: 800-804.
Hiremath J, Thanikachalam S, Parikh K et al. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. J Heart Lung Transplant, 2010; 29: 137-149.
Tapson VF, Gomberg-Maitland M, McLaughlin VV et al. Safety and efficacy of IV treprostinil for pulmonary arterialhypertension: a prospective, multicenter, open-label, 12-week trial. Chest, 2006; 129: 683-688.
Sitbon O, Manes A, Jaïs X et al. Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension. J Cardiovasc Pharmacol, 2007; 49: 1-5.
McLaughlin V, Rubin L, Benza RL et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol, 2010; 55: 1915-1922.
Tapson VF, Torres F, Kermeen F et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest, 2012; 142: 1383-1390.
Tapson VF, Jing ZC, Xu KF et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Chest, 2013; 144: 952-958.
Jing ZC, Parikh K, Pulido T et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation, 2013; 127: 624-633.
Simonneau G, Torbicki A, Hoeper MM et al. Selexipag, an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J, 2012; 40: 874-880.
Chen SL, Zhang FF, Xu J et al. Pulmonary artery denervation to treat pulmonary arterial hypertension: the single-center, prospective, first-in-man PADN-1 study (first-in-man pulmonary artery denervation for treatment of pulmonary artery hypertension). J Am Coll Cardiol, 2013; 62: 1092-1100.
Galiè N, Manes A. New treatment strategies for pulmonary arterial hypertension: hopes or hypes? J Am Coll Cardiol, 2013; 62: 1101-1102.
Galiè N, Palazzini M, Manes A. Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses. Eur Heart J, 2010; 31: 2080-2086.
Kemp K, Savale L, O'Callaghan DS et al. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. J Heart Lung Transplant, 2012; 31: 150-158.
Sitbon O, Jaïs X, Savale L et al. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J, 2014; 43: 1691-1697.
Galiè N, Barbera JA, Frost A et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. New Engl J Med, 2015; 379: 834-844.
McLaughlin VV, Channick R, Chin KM et al. Effect of selexipag on morbidity/mortality in pulmonary arterial hypertension: results of the GRIPHON study. J Am Coll Cardiol, 2015; 65 (suppl. A): A380.
Badesch BD, Feldman J, Keogh A et al. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. Cardiovasc Ther, 2012; 30: 93-99.
Provencher S, Sitbon O, Humbert M et al. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J, 2006; 27: 589-595.
McLaughlin V, Channick RN, Ghofrani HA et al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J, 2015; 46: 405-413.
Dardi F, Manes A, Palazzini M et al. Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: real-world insights. Eur Respir J, 2015; 46: 414-421.
Sandoval J, Gaspar J, Pulido T et al. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. J Am Coll Cardiol, 1998; 32: 297-304.
Kurzyna M, Dabrowski M, Bielecki D et al. Atrial septostomy in treatment of end-stage right heart failure in Patients with pulmonary hypertension. Chest, 2007; 131: 977-983.
Althoff TF, Knebel F, Panda A et al. Long-term follow-up of a fenestrated Amplatzer atrial septal occlude in pulmonary arterial hypertension. Chest, 2008; 133: 283-285.
Keogh A, Benza RL, Corris P et al. Interventional and surgical modalities of treatment in pulmonary arterial hypertension. J Am Coll Cardiol, 2009; 54(suppl.): S67-S77.
Sztrymf B, Souza R, Bertoletti I et al. Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension. Eur Respir J, 2010; 35: 1286-1293.
Zamanian RT, Haddad F, Doyle RL, Weinacker AB. Management strategies for patients with pulmonary hypertension in the intensive care unit. Crit Care Med, 2007; 35: 2037-2050.
Price LC, Wort SJ, Finney SJ et al. Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review. Crit Care, 2010; 14: R169.
Hoeper MM, Granton J. Intensive care unit management of patients with severe pulmonary hypertension and right heart failure. Am J Respir Crit Care Med, 2011; 184: 1114-1124.
Rosenzweig EB, Brodie D, Abrams DC et al. Extracorporeal membrane oxygenation as a novel bridging strategy for acute right heart failure in group 1 pulmonary arterial hypertension. ASAIO J, 2014; 60: 129-133.
Olsson KM, Simon A, Strueber M et al. Extracorporeal membrane oxygenation in nonintubated patients as bridge to lung transplantation. Am J Transplant, 2010; 10: 2173-2178.
Fuehner T, Kuehn C, Hadem J et al. Extracorporeal membrane oxygenation in awake patients as bridge to lung transplantation. Am J Respir Crit Care Med, 2012; 185: 763-768.
de Perrot M, Granton JT, McRae K et al. Impact of extracorporeal life support on outcome in patients with idiopathic pulmonary arterial hypertension awaiting lung transplantation. J Heart Lung Transplant, 2011; 30: 997-1002.
Strueber M, Hoeper MM, Fischer S et al. Bridge to thoracic organ transplantation in patients with pulmonary arterial hypertension using a pumpless lung assist device. Am J Transplant, 2009; 9: 853-857.
Trulock EP, Edwards LB, Taylor DO et al. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult lung and heart lung transplantation report - 2006. J Heart Lung Transplant, 2006; 25: 880-892.
Toyoda Y, Thacker J, Santos R et al. Long-term outcome of lung and heart-lung transplantation for idiopathic pulmonary arterial hypertension. Ann Thorac Surg, 2008; 86: 1116-1122.
Fadel E, Mercier O, Mussot S et al. Long-term outcome of double-lung and heart2lung transplantation for pulmonary hypertension: a comparative retrospective study of 219 patients. Eur J Cardiothorac Surg, 2010; 38: 277-284.
de Perrot M, Granton JT, McRae K et al. Outcome of patients with pulmonary arterial hypertension referred for lung transplantation: a 14-year single-center experience. J Thorac Cardiovasc Surg, 2012; 143: 910-918.
Christie JD, Edwards LB, Kucheryavaya AY et al. The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report - 2012. J Heart Lung Transplant, 2012; 31: 1073-1086.
Waddell TK, Bennett L, Kennedy R et al. Heart-lung or lung transplantation for Eisenmenger syndrome. J Heart Lung Transplant, 2002; 21: 731-737.
Choong CK, Sweet SC, Guthrie TJ et al. Repair of congenital heart lesions combined with lung transplantation for the treatment of severe pulmonary hypertension: a 13-year experience. J Thorac Cardiovasc Surg, 2005; 129: 661-669.
Fleming TR, Powers JH. Biomarkers and surrogate endpoints in clinical trials. Statistic Med, 2012; 31: 2973-2984.
Fleming TR. Surrogate endpoints and FDA accelerated approval process. Health Affairs, 2005; 24: 67-78.
Tongers J, Schwerdtfeger B, Klein G et al. Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. Am Heart J, 2007; 153: 127-132.
Hoeper MM, Galiè N, Murali S et al. Outcome after cardiopulmonary resuscitation in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med, 2002; 165: 341-344.
Showkathali R, Tayebjee MH, Grapsa J et al. Right atrial flutter isthmus ablation is feasible and results in acute clinical improvement in patients with persistent atrial flutter and severe pulmonary arterial hypertension. Int J Cardiol, 2011; 149: 279-280.
Zylkowska J, Kurzyna M, Pietura R et al. Recurrent hemoptysis: an emerging life-threatening complication in idiopathic pulmonary arterial hypertension. Chest, 2011; 139: 690-693.
Zylkowska J, Kurzyna M, Florczyk M et al. Pulmonary artery dilatation correlates with the risk of unexpected death in chronic arterial or thromboembolic pulmonary hypertension. Chest, 2012; 142: 1406-1416.
Russo V, Zompatori M, Galiè N. Extensive right pulmonary artery dissection in a young patient with chronic pulmonary hypertension. Heart, 2012; 98: 265-266.
Demerouti EA, Manginas AN, Athanassopoulos GD, Karatasakis GT. Complications leading to sudden cardiac death in pulmonary arterial hypertension. Respir Care, 2013; 58: 1246-1254.
Lee MS, Oyama J, Bhatia R et al. Left main coronary artery compression from pulmonary artery enlargement due to pulmonary hypertension: a contemporary review and argument for percutaneous revascularization. Catheter Cardiovasc Interv, 2010; 76: 543-550.
Barst RJ, Ertel SI, Beghetti M, Ivy DD. Pulmonary arterial hypertension: a comparison between children and adults. Eur Respir J, 2011; 37: 665-677.
Barst RJ, McGoon MD, Elliott CG et al. Survival in childhood pulmonary arterial hypertension. Circulation, 2012; 125: 113-122.
van Loon RL, Roofthooft MTR, Hillege HL et al. Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005. Circulation, 2011; 124: 1755-1764.
Moledina S, Hislop AA, Foster H et al. Childhood idiopathic pulmonary arterial hypertension: a national cohort study. Heart, 2010; 96: 1401-1406.
Berger RM, Beghetti M, Humpl T et al. Clinical features of paediatric pulmonary hypertension: a registry study. Lancet, 2012; 379: 537-546.
Hansmann G, Hoeper MM. Registries for paediatric pulmonary hypertension. Eur Respir J, 2013; 42: 580-583.
Cerro MJ, Abman S, Diaz G et al. A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: report from the PVRI Pediatric Taskforce, Panama 2011. Pulm Circ, 2011; 1: 286-298.
Beghetti M, Berger RM, Schulze-Neick I et al. Diagnostic evaluation of paediatric pulmonary hypertension in current clinical practice. Eur Respir J, 2013; 42: 689-700.
Schulze-Neick I, Beghetti M. Issues related to the management and therapy of paediatric pulmonary hypertension. Eur Respir Rev, 2010; 19: 331-339.
Adatia I, Haworth SG, Wegner M et al. Clinical trials in neonates and children: report of the Pulmonary Hypertension Academic Research Consortium Pediatric Advisory Committee. Pulm Circ, 2013; 3: 252-266.
Lammers AE, Hislop AA, Flynn Y, Haworth SG. Epoprostenol treatment in children with severe pulmonary hypertension. Heart, 2007; 93: 739-743.
Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. Circulation, 1999; 99: 1197-1208.
Levy M, Celermajer DS, Bourges-Petit E et al. Add-on therapy with subcutaneous treprostinil for refractory pediatric pulmonary hypertension. J Pediatr, 2011; 158: 584-588.
Ivy DD, Doran AK, Smith KJ et al. Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol, 2008; 51: 161-169.
Barst R, Ivy D, Widlitz AC et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther, 2003; 73: 372-382.
Rosenzweig EB, Ivy DD, Widlitz A et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol, 2005; 46: 697-704.
Beghetti M, Haworth SG, Bonnet D et al. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study. Br J Clin Pharmacol, 2009; 68: 948-955.
Barst RJ, Ivy DD, Gaitan G et al. A randomized, doubleblind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation, 2012; 125: 324-334.
Barst RJ, Beghetti M, Pulido T et al. STARTS-2: long-term survival with oral sildenafil monotherapy in treatmentnaive pediatric pulmonary arterial hypertension. Circulation, 2014; 129: 1914-1923.
Takatsuki S, Calderbank M, Ivy DD. Initial experience with tadalafil in pediatric pulmonary arterial hypertension. Pediatr Cardiol, 2012; 33: 683-688.
Douwes JM, Roofthooft MT, Van Loon RL et al. Sildenafil add-on therapy in paediatric pulmonary arterial hypertension, experiences of a national referral centre. Heart, 2014; 100: 224-230.
Micheletti A, Hislop AA, Lammers A et al. Role of atrial septostomy in the treatment of children with pulmonary arterial hypertension. Heart, 2006; 92: 969-972.
Boudjemline Y, Patel M, Malekzadeh-Milani S et al. Patent ductus arteriosus stenting (transcatheter Potts shunt) for palliation of suprasystemic pulmonary arterial hypertension: a case series. Circ Cardiovasc Interv, 2013; 6: e18-e20.
Baruteau AE, Belli E, Boudjemline Y et al. Palliative Potts shunt for the treatment of children with drug-refractory pulmonary arterial hypertension: updated data from the first 24 patients. Eur J Cardiothorac Surg, 2015; 47: e105-e110.
Esch JJ, Shah PB, Cockrill BA et al. Transcatheter Potts shunt creation in patients with severe pulmonary arterial hypertension: initial clinical experience. J Heart Lung Transplant, 2013; 32: 381-387.
Ploegstra MJ, Douwes JM, Roofthooft MT et al. Identification of treatment goals in paediatric pulmonary arterial hypertension. Eur Respir J, 2014; 44: 1616-1626.
Galiè N, Manes A, Palazzini M et al. Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger's syndrome. Drugs, 2008; 68: 1049-1066.
Engelfriet PM, Duffels MGJ, Moller T et al. Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease. Heart, 2007; 93: 682-687.
Beghetti M, Galiè N. Eisenmenger syndrome: a clinical perspective in a new therapeutic era of pulmonary arterial hypertension. J Am Coll Cardiol, 2009; 53: 733-740.
Daliento L, Somerville J, Presbitero P et al. Eisenmenger syndrome. Factors relating to deterioration and death. Eur Heart J, 1998; 19: 1845-1855.
Hopkins WE, Ochoa LL, Richardson GW, Trulock EP. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant, 1996; 15: 100-105.
Manes A, Palazzini M, Leci E et al. Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups. Eur Heart J, 2014; 35: 716-724.
Hopkins WE. The remarkable right ventricle of patients with Eisenmenger syndrome. Coron Artery Dis, 2005; 16: 19-25.
Diller GP, Gatzoulis MA. Pulmonary vascular disease in adults with congenital heart disease. Circulation, 2007; 115: 1039-1050.
Moller JH, Patton C, Varco RL, Lillehei CW. Late results (30 to 35 years) after operative closure of isolated ventricular septal defect from 1954 to 1960. Am J Cardiol, 1991; 68: 1491-1497.
van Albada ME, Berger RM. Pulmonary arterial hypertension in congenital cardiac disease - the need for refinement of the Evian-Venice classification. Cardiol Young, 2008; 18: 10-17.
Schulze-Neick I, Beghetti M. Classifying pulmonary hypertension in the setting of the congenitally malformed heart - cleaning up a dog's dinner. Cardiol Young, 2008; 18: 22-25.
Lopes AA, Leary PW. Measurement, interpretation and use of hemodynamic parameters. Cardiol Young, 2009; 19 (suppl. 1): 8-12.
Broberg CS, Ujita M, Prasad S et al. Pulmonary arterial thrombosis in Eisenmenger syndrome is associated with biventricular dysfunction and decreased pulmonary flow velocity. J Am Coll Cardiol, 2007; 50: 634-642.
Gatzoulis MA, Beghetti M, Galiè N et al. Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study. Int J Cardiol, 2007; 127: 27-32.
Zuckerman WA, Leaderer D, Rowan CA et al. Ambrisentan for pulmonary arterial hypertension due to congenital heart disease. J Am Coll Cardiol, 2011; 107: 1381-1385.
Mukhopadhyay S, Sharma M, Ramakrishnan S et al. Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a preliminary observational study. Circulation, 2006; 114: 1807-1810.
Khanna D, Gladue H, Channick R et al. Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension. Arthritis Rheum, 2013; 65: 3194-3201.
Gashouta MA, Humbert M, Hassoun PM. Update in systemic sclerosis-associated pulmonary arterial hypertension. Presse Med, 2014; 43: e293-e304.
Coghlan JG, Denton CP, Gruenig E et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis, 2014; 73: 1340-1349.
Humbert M, Yaici A, de Groote P et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum, 2011; 63: 3522-3530.
Hao YJ, Jiang X, Zhou W et al. Connective tissue disease-associated pulmonary arterial hypertension in Chinese patients. Eur Respir J, 2014; 44: 963-972.
Hachulla E, Carpentier P, Gressin V et al. Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinerAIR-Sclerodermie study. Rheumatology, 2009; 48: 304-308.
Avouac J, Airo P, Meune C et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumatol, 2010; 37: 2290-2298.
Gunther S, Jaïs X, Maitre S et al. Computed tomography findings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pulmonary hypertension. Arthritis Rheum, 2012; 64: 2995-3005.
Coghlan G. Does left heart disease cause most systemic sclerosis associated pulmonary hypertension? Eur Respir J, 2013; 42: 888-890.
Humbert M, Sitbon O, Yaïci A et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J, 2010; 36: 549-555.
Fisher MR, Mathai SC, Champion HC et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum, 2006; 54: 3043-3050.
Launay D, Sitbon O, Hachulla E et al. Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. Ann Rheum Dis, 2013; 72: 1940-1946.
O'Callaghan DS, Dorfmuller P, Jaïs X et al. Pulmonary veno-occlusive disease: the bete noire of pulmonary hypertension in connective tissue diseases? Presse Med, 2011; 40: e65-e78.
Demling RH, Smith M, Gunther R et al. Pulmonary injury and prostaglandin production during endotoxemia in conscious sheep. Am J Physiol, 1981; 240: H348-H353.
Jaïs X, Launay D, Yaïci A et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum, 2008; 58: 521-531.
Avouac J, Wipff J, Kahan A, Allanore Y. Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials. Ann Rheum Dis, 2008; 67: 808-814.
Launay D, Savale L, Berezne A et al. Lung and heart-lung transplantation for systemic sclerosis patients. A monocentric experience of 13 patients, review of the literature and position paper of a multidisciplinary working group. Presse Med, 2014; 43: e345-e363.
Hoeper MM, Krowka MJ, Strassburg CP. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet, 2004; 363: 1461-1468.
Zopey R, Susanto I, Barjaktarevic I, Wang T. Transition from hepatopulmonary syndrome to portopulmonary hypertension: a case series of 3 patients. Case Rep Pulmonol, 2013; 2013: 561870.
Krowka MJ, Swanson KL, Frantz RP et al. Portopulmonary hypertension: results from a 10-year screening algorithm. Hepatology, 2006; 44: 1502-1510.
Kawut SM, Krowka MJ, Trotter JF et al. Clinical risk factors for portopulmonary hypertension. Hepatology, 2008; 48: 196-203.
Roberts KE, Fallon MB, Krowka MJ et al. Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med, 2009; 179: 835-842.
Krowka MJ, Miller DP, Barst RJ et al. Portopulmonary hypertension: a report from the US-based REVEAL Registry. Chest, 2012; 141: 906-915.
Le Pavec J, Souza R, Herve P et al. Portopulmonary hypertension: survival and prognostic factors. Am J Respir Crit Care Med, 2008; 178: 637-643.
Provencher S, Herve P, Jaïs X et al. Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology, 2006; 130: 120-126.
Hoeper MM, Seyfarth HJ, Hoeffken G et al. Experience with inhaled iloprost and bosentan in portopulmonary hypertension. Eur Respir J, 2007; 30: 1096-1102.
Halank M, Knudsen L, Seyfarth HJ et al. Ambrisentan improves exercise capacity and symptoms in patients with portopulmonary hypertension. Z Gastroenterol, 2011; 49: 1258-1262.
Reichenberger F, Voswinckel R, Steveling E et al. Sildenafil treatment for portopulmonary hypertension. Eur Respir J, 2006; 28: 563-567.
Kuo PC, Johnson LB, Plotkin JS et al. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation, 1997; 63: 604-606.
Swanson KL, Wiesner RH, Nyberg SL et al. Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups. Am J Transplant, 2008; 8: 2445-2453.
Sakai T, Planinsic RM, Mathier MA et al. Initial experience using continuous intravenous treprostinil to manage pulmonary arterial hypertension in patients with end-stage liver disease. Transpl Int, 2009; 22: 554-561.
Savale L, Magnier R, Le Pavec J et al. Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension. Eur Respir J, 2013; 41: 96-103.
Humbert M, Segal ES, Kiely DG et al. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J, 2007; 30: 338-344.
Kia L, Shah SJ, Wang E et al. Role of pretransplant echocardiographic evaluation in predicting outcomes following liver transplantation. Am J Transplant, 2013; 13: 2395-2401.
Krowka MJ, Plevak DJ, Findlay JY et al. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transplant, 2000; 6: 443-450.
Ashfaq M, Chinnakotla S, Rogers L et al. The impact of treatment of portopulmonary hypertension on survival following liver transplantation. Am J Transplant, 2007; 7: 1258-1264.
Raevens S, De Pauw M, Reyntjens K et al. Oral vasodilator therapy in patients with moderate to severe portopulmonary hypertension as a bridge to liver transplantation. Eur J Gastroenterol Hepatol, 2013; 25: 495-502.
Plotkin JS, Kuo PC, Rubin LJ et al. Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension. Transplantation, 1998; 65: 457-459.
Austin MJ, McDougall NI, Wendon JA et al. Safety and efficacy of combined use of sildenafil, bosentan, and iloprost before and after liver transplantation in severe portopulmonary hypertension. Liver Transplant, 2008; 14: 287-291.
Grannas G, Neipp M, Hoeper MM et al. Indications for and outcomes after combined lung and liver transplantation: a single-center experience on 13 consecutive cases. Transplantation, 2008; 85: 524-531.
Robalino BD, Moodie DS. Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations. J Am Coll Cardiol, 1991; 17: 492-498.
Barbaro G, Lucchini A, Pellicelli AM et al. Highly active antiretroviral therapy compared with HAART and bosentan in combination in patients with HIV-associated pulmonary hypertension. Heart, 2006; 92: 1164-1166.
Degano B. HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. AIDS, 2010; 24: 67-75.
Opravil M, Pechère M, Speich R et al. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med, 1997; 155: 990-995.
Sitbon O, Lascoux-Combe C, Delfraissy JF et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med, 2008; 177: 108-113.
Sitbon O, Gressin V, Speich R et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med, 2004; 170: 1212-1217.
Montani D, Achouh L, Dorfmuller P et al. Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicine (Baltimore), 2008; 87: 220-233.
Lantuejoul S, Sheppard MN, Corrin B et al. Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis: a clinicopathologic study of 35 cases. Am J Surg Pathol, 2006; 30: 850-857.
Humbert M, Maître S, Capron F et al. Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis. Am J Respir Crit Care Med, 1998; 157: 1681-1685.
Mandel J, Mark EJ, Hales CA. Pulmonary veno-occlusive disease. Am J Respir Crit Care Med, 2000; 162: 1964-1973.
Langleben D, Heneghan JM, Batten AP et al. Familial pulmonary capillary hemangiomatosis resulting in primary pulmonary hypertension. Ann Intern Med, 1988; 109: 106-109 [published erratum appears in Ann Intern Med, 1988; 109: 439].
Best DH, Sumner KL, Austin ED et al. EIF2AK4 mutations in pulmonary capillary hemangiomatosis. Chest, 2014; 145: 231-236.
Seferian A, Helal B, Jaïs X et al. Ventilation/perfusion lung scan in pulmonary veno-occlusive disease. Eur Respir J, 2012; 40: 75-83.
Rabiller A, Jaïs X, Hamid A et al. Occult alveolar haemorrhage in pulmonary veno-occlusive disease. Eur Respir J, 2006; 27: 108-113.
Montani D, Jaïs X, Price LC et al. Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease. Eur Respir J, 2009; 34: 1348-1356.
Fang JC, DeMarco T, Givertz MM et al. World Health Organization Pulmonary Hypertension Group 2: pulmonary hypertension due to left heart disease in the adult - a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant, 2012; 31: 913-933.
Ghio S, Gavazzi A, Campana C et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol, 2001; 37: 183-188.
Thenappan T, Shah SJ, Gomberg-Maitland M et al. Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction. Circ Heart Fail, 2011; 4: 257-265.
Robbins IM, Newman JH, Johnson RF et al. Association of the metabolic syndrome with pulmonary venous hypertension. Chest, 2009; 136: 31-36.
Bursi F, McNallan SM, Redfield MM et al. Pulmonary pressures and death in heart failure: a community study. J Am Coll Cardiol, 2012; 59: 222-231.
Gerges C, Gerges M, Lang MB et al. Diastolic pulmonary vascular pressure gradient: a predictor of prognosis in "out-of-proportion" pulmonary hypertension. Chest, 2013; 143: 758-766.
Moraes DL, Colucci WS, Givertz MM. Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Circulation, 2000; 102: 1718-1723.
Rapp AH, Lange RA, Cigarroa JE et al. Relation of pulmonary arterial diastolic and mean pulmonary arterial wedge pressures in patients with and without pulmonary hypertension. Am J Cardiol, 2001; 88: 823-824.
Miller WL, Grill DE, Borlaug BA. Clinical features, hemodynamics, and outcomes of pulmonary hypertension due to chronic heart failure with reduced ejection fraction: pulmonary hypertension and heart failure. JACC Heart Fail, 2013; 1: 290-299.
Tampakakis E, Leary PJ, Selby VN et al. The diastolic pulmonary gradient does not predict survival in patients with pulmonary hypertension due to left heart disease. JACC Heart Fail, 2015; 3: 9-16.
Pellegrini P, Rossi A, Pasotti M et al. Prognostic relevance of pulmonary arterial compliance in patients with chronic heart failure. Chest, 2014; 145: 1064-1070.
Chatterjee NA, Lewis GD. Characterization of pulmonary hypertension in heart failure using the diastolic pressure gradient: limitations of a solitary measurement. JACC Heart Fail, 2015; 3: 17-21.
McMurray JJ, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J, 2012; 33: 1787-1847.
Khush KK, Tasissa G, Butler J et al. Effect of pulmonary hypertension on clinical outcomes in advanced heart failure: analysis of the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) database. Am Heart J, 2009; 157: 1026-1034.
Patel ND, Weiss ES, Schaffer J et al. Right heart dysfunction after left ventricular assist device implantation: a comparison of the pulsatile Heart Mate I and axial-flow Heart Mate II devices. Ann Thorac Surg, 2008; 86: 832-840.
Torre-Amione G, Southard RE, Loebe MM et al. Reversal of secondary pulmonary hypertension by axial and pulsatile mechanical circulatory support. J Heart Lung Transplant, 2010; 29: 195-200.
Barnett CF, DeMarco T. Pulmonary hypertension associated with left-sided heart disease. Heart Fail Clin, 2012; 8: 447-459.
Bonderman D, Ghio S, Felix SB et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation, 2013; 128: 502-511.
Oswald-Mammosser M, Weitzenblum E, Quoix E et al. Prognostic factors in COPD patients receiving longterm oxygen therapy. Importance of pulmonary artery pressure. Chest, 1995; 107: 1193-1198.
Kessler R, Faller M, Weitzenblum E et al. "Natural history" of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease. Am J Respir Crit Care Med, 2001; 164: 219-224.
Lettieri CJ, Nathan SD, Barnett SD et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest, 2006; 129: 746-752.
Thabut G, Dauriat G, Stern JB et al. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest, 2005; 127: 1531-1536.
Chaouat A, Bugnet AS, Kadaoui N et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2005; 172: 189-194.
Arcasoy SM, Christie JD, Ferrari VA et al. Echocardiographic assessment of pulmonary hypertension in patients with advance lung disease. Am J Respir Crit Care Med, 2003; 167: 735-740.
Fisher MR, Forfia PR, Chamera E et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med, 2009; 179: 615-621.
Nathan SD, Shlobin OA, Barnett SD et al. Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fibrosis. Respir Med, 2008; 102: 1305-1310.
Agusti AG, Barbera JA, Roca J et al. Hypoxic pulmonary vasoconstriction and gas exchange during exercise in chronic obstructive pulmonary disease. Chest, 1990; 97: 268-275.
Barbera JA, Roger N, Roca J et al. Worsening of pulmonary gas exchange with nitric oxide inhalation in chronic obstructive pulmonary disease. Lancet, 1996; 347: 436-440.
Simonneau G, Escourrou P, Duroux P, Lockhart A. Inhibition of hypoxic pulmonary vasoconstriction by nifedipine. N Engl J Med, 1981; 304: 1582-1585.
Morrell NW, Higham MA, Phillips PG et al. Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease. Respir Res, 2005; 6: 88-95.
Saadjian A, Philip-Joet F, Paganelli F et al. Long-term effects of cicletanine on secondary pulmonary hypertension. J Cardiovasc Pharmacol, 1998; 31: 364-371.
Stolz D, Rasch H, Linka A et al. A randomised, controlled trial of bosentan in severe COPD. Eur Respir J, 2008; 32: 619-628.
Blanco I, Gimeno E, Munoz PA et al. Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am J Respir Crit Care Med, 2010; 181: 270-278.
Zisman DA, Schwarz M, Anstrom KJ et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med, 2010; 363: 620-628.
Blanco I, Santos S, Gea J et al. Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial. Eur Respir J, 2013; 42: 982-992.
Lederer DJ, Bartels MN, Schluger NW et al. Sildenafil for chronic obstructive pulmonary disease: a randomized crossover trial. COPD, 2012; 9: 268-275.
Goudie AR, Lipworth BJ, Hopkinson PJ et al. Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Respir Med, 2014; 2: 293-300.
Lang IM, Pesavento R, Bonderman D, Yuan JX. Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding. Eur Respir J, 2013; 41: 462-468.
Guerin L, Couturaud F, Parent F et al. Prevalence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Prevalence of CTEPH after pulmonary embolism. Thromb Haemost, 2014; 112: 598-605.
Pepke-Zaba J, Jansa P, Kim NH et al. Chronic thromboembolic pulmonary hypertension: role of medical therapy. Eur Respir J, 2013; 41: 985-990.
Madani MM, Wittine LM, Auger WR et al. Chronic thromboembolic pulmonary hypertension in pediatric patients. J Thorac Cardiovasc Surg, 2011; 141: 624-630.
Pepke-Zaba J, Hoeper MM, Humbert M. Chronic thromboembolic pulmonary hypertension: advances from bench to patient management. Eur Respir J, 2013; 41: 8-9.
Lang IM, Simonneau G, Pepke-Zaba JW et al. Factors associated with diagnosis and operability of chronic thromboembolic pulmonary hypertension. A case-control study. Thromb Haemost, 2013; 110: 83-91.
Lang IM, Plank C, Sadushi-Kolici R et al. Imaging in pulmonary hypertension. JACC Cardiovasc Imaging, 2010; 3: 1287-1295.
Hoeper MM, Mayer E, Simonneau G, Rubin LJ. Chronic thromboembolic pulmonary hypertension. Circulation, 2006; 113: 2011-2020.
Sherrick AD, Swensen SJ, Hartman TE. Mosaic pattern of lung attenuation on CT scans: frequency among patients with pulmonary artery hypertension of different causes. Am J Roentgenol, 1997; 169: 79-82.
Ley S, Ley-Zaporozhan J, Pitton MB et al. Diagnostic performance of state-of-the-art imaging techniques for morphological assessment of vascular abnormalities in patients with chronic thromboembolic pulmonary hypertension (CTEPH). Eur Radiol, 2012; 22: 607-616.
Sugiyama M, Fukuda T, Sanda Y et al. Organized thrombus in pulmonary arteries in patients with chronic thromboembolic pulmonary hypertension; imaging with cone beam computed tomography. Jpn J Radiol, 2014; 32: 375-382.
Shure D, Gregoratos G, Moser KM. Fiberoptic angioscopy: role in the diagnosis of chronic pulmonary arterial obstruction. Ann Intern Med, 1985; 103: 844-850.
Skoro-Sajer N, Marta G, Gerges C et al. Surgical specimens, haemodynamics and long-term outcomes after pulmonary endarterectomy. Thorax, 2014; 69: 116-122.
Mayer E, Jenkins D, Lindner J et al. Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. J Thorac Cardiovasc Surg, 2011; 141: 702-710.
Madani MM, Auger WR, Pretorius V et al. Pulmonary endarterectomy: recent changes in a single institution's experience of more than 2,700 patients. Ann Thorac Surg, 2012; 94: 97-103.
Jenkins D, Mayer E, Screaton N, Madani M. State-of-the-art chronic thromboembolic pulmonary hypertension diagnosis and management. Eur Respir Rev, 2012; 21: 32-39.
Vuylsteke A, Sharples L, Charman G et al. Circulatory arrest versus cerebral perfusion during pulmonary endarterectomy surgery (PEACOG): a randomised controlled trial. Lancet, 2011; 378: 1379-1387.
Thistlethwaite PA, Madani MM, Kemp AD et al. Venovenous extracorporeal life support after pulmonary endarterectomy: indications, techniques, and outcomes. Ann Thorac Surg, 2006; 82: 2139-2145.
Berman M, Tsui S, Vuylsteke A et al. Successful extracorporeal membrane oxygenation support after pulmonary thromboendar-terectomy. Ann Thorac Surg, 2008; 86: 1261-1267.
Mydin M, Berman M, Klein A et al. Extracorporeal membrane oxygenation as a bridge to pulmonary endarterectomy. Ann Thorac Surg, 2011; 92: e101-e103.
Hughes RJ, Jaïs X, Bonderman D et al. The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study. Eur Respir J, 2006; 28: 138-143.
Skoro-Sajer N, Bonderman D, Wiesbauer F et al. Treprostinil for severe inoperable chronic thromboembolic pulmonary hypertension. Thromb Haemost, 2007; 5: 483-489.
Reichenberger F, Voswinckel R, Enke B et al. Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension. Eur Respir J, 2007; 30: 922-927.
Jaïs X, D'Armini AM, Jansa P et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol, 2008; 52: 2127-2134.
Ghofrani HA, D'Armini AM, Grimminger F et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med, 2013; 369: 319-329.
Reesink HJ, Surie S, Kloek JJ et al. Bosentan as a bridge to pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. J Thorac Cardiovasc Surg, 2010; 139: 85-91.
Feinstein JA, Goldhaber SZ, Lock JE et al. Balloon pulmonary angioplasty for treatment of chronic thromboembolic pulmonary hypertension. Circulation, 2001; 103: 10-13.
Kataoka M, Inami T, Hayashida K et al. Percutaneous transluminal pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv, 2012; 5: 756-762.
Mizoguchi H, Ogawa A, Munemasa M et al. Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv, 2012; 5: 748-755.
Sugimura K, Fukumoto Y, Satoh K et al. Percutaneous transluminal pulmonary angioplasty markedly improves pulmonary hemodynamics and long-termprognosis in patients with chronic thromboembolic pulmonary hypertension. Circ J, 2012; 76: 485-488.
Inami T, Kataoka M, Shimura N et al. Pulmonary edema predictive scoring index (PEPSI), a new index to predict risk of reperfusion pulmonary edema and improvement of hemodynamics in percutaneous transluminal pulmonary angioplasty. JACC Cardiovasc Interv, 2013; 6: 725-736.
Andreassen AK, Ragnarsson A, Gude E et al. Balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension. Heart, 2013; 99: 1415-1420.
Rubin LJ, Hoeper MM, Klepetko W et al. Current and future management of chronic thromboembolic pulmonary hypertension: from diagnosis to treatment responses. Proc Am Thorac Soc, 2006; 3: 601-607.
Peacock A. Pulmonary hypertension due to chronic hypoxia. BMJ, 1990; 300: 763.
Recommendations on the management of pulmonary hypertension in clinical practice. Heart, 2001; 86 (suppl. 1): I1-I13.
Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland. Thorax, 2008; 63 (suppl. 2): ii1-ii41.
Barbera JA, Escribano P, Morales P et al. Standards of care in pulmonary hypertension. Consensus statement of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) and the Spanish Society of Cardiology (SEC). Rev Esp Cardiol, 2008; 61: 170-184.
Armstrong I, Rochnia N, Harries C et al. The trajectory to diagnosis with pulmonary arterial hypertension: a qualitative study. BMJ Open, 2012; 2: e000806.
Ghofrani HA, Distler O, Gerhardt F et al. Treatment of pulmonary arterial hypertension (PAH): updated Recommendations of the Cologne Consensus Conference 2011. Int J Cardiol, 2011; 154 (suppl. 1): S20-S33.
Vachiery JL, Gaine S. Challenges in the diagnosis and treatment of pulmonary arterial hypertension. Eur Respir Rev, 2012; 21: 313-320.
Simonneau G, Gatzoulis MA, Adatia I et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol, 2013; 62: D34-D41.
Simonneau G, Galiè N, Rubin LJ et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol, 2004; 43 (suppl. 1): S5-S12.
Ivy DD, Abman SH, Barst RJ et al. Pediatric pulmonary hypertension. J Am Coll Cardiol, 2013; 62: D117-D126.
Sitbon O, Brenot F, Denjean A et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med, 1995; 151: 384-389.
Sitbon O, Humbert M, Jaïs X et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation, 2005; 111: 3105-3111.
Galiè N, Ussia G, Passarelli P et al. Role of pharmacologic tests in the treatment of primary pulmonary hypertension. Am J Cardiol, 1995; 75: 55A-62A.
Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76-81.
Jing ZC, Jiang X, Han ZY et al. Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension. Eur Respir J, 2009; 33: 1354-1360.
Barst RJ, McGoon M, Torbicki A et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol, 2004; 43 (suppl. 1): S40-S47.
Galiè N, Olschewski H, Oudiz RJ et al. Ambrisentan for the treatment of pulmonary arterial hypertension. Results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation, 2008; 117: 3010-3019.
Channick RN, Simonneau G, Sitbon O et al. Effects of the dual endothelinreceptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet, 2001; 358: 1119-1123.
Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med, 2002; 346: 896-903.
Galiè N, Rubin LJ, Hoeper M et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomized controlled trial. Lancet, 2008; 371: 2093-2100.
Galiè N, Beghetti M, Gatzoulis MA et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation, 2006; 114: 48-54.
McLaughlin V, Channick RN, Ghofrani HA et al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J, 2015; 46: 405-413.
Pulido T, Adzerikho I, Channick RN et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. New Engl J Med, 2013; 369: 809-818.
Ghofrani HA, Galiè N, Grimminger F et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013;369:330-340.
Galiè N, Muller K, Scalise AV, Grunig E. PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in PAH. Eur Respir J, 2015; 45: 1314-1322.
Galiè N, Ghofrani HA, Torbicki A et al. Sildenafil citrate therapy for pulmonary arterial hypertension. New Engl J Med, 2005; 353: 2148-2157.
Sastry BKS, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol, 2004; 43: 1149-1153.
Singh T, Rohit M, Grover A et al. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J, 2006;151:851.e1-851. e5.
Simonneau G, Rubin L, Galiè N et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension. Ann Intern Med, 2008; 149: 521-530.
Iversen K, Jensen AS, Jensen TV et al. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Eur Heart J, 2010; 31: 1124-1131.
Galiè N, Brundage BH, Ghofrani HA et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation, 2009; 119: 2894-2903.
Jing ZC, Yu ZX, Shen JY et al. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med, 2011; 183: 1723-1729.
Galiè N, Humbert M, Vachiery JL et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomised, double-blind placebocontrolled trial. J Am Coll Cardiol, 2002; 39: 1496-1502.
Barst RJ, McGoon M, McLaughlin VV et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol, 2003; 41: 2119-2125.
Rubin LJ, Mendoza J, Hood M et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med, 1990; 112: 485-491.
Barst RJ, Rubin LJ, Long WA et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med, 1996; 334: 296-302.
Badesch DB, Tapson VF, McGoon MD et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial [see comments]. Ann Intern Med, 2000; 132: 425-434.
Olschewski H, Simonneau G, Galiè N et al. Inhaled iloprost in severe pulmonary hypertension. N Engl J Med, 2002; 347: 322-329.
McLaughlin VV, Oudiz RJ, Frost A et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med, 2006; 174: 1257-1263.
Hoeper M, Leuchte H, Halank M et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J, 2006; 4: 691-694.
Simonneau G, Barst RJ, Galiè N et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. A double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med, 2002; 165: 800-804.
McLaughlin V, Rubin L, Benza RL et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol, 2010; 55: 1915-1922.
Jing ZC, Parikh K, Pulido T et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation, 2013; 127: 624-633.
Tapson VF, Torres F, Kermeen F et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest, 2012; 142: 1383-1390.
Tapson VF, Jing ZC, Xu KF et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Chest, 2013; 144: 952-958.
Simonneau G, Torbicki A, Hoeper MM et al. Selexipag, an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J, 2012; 40: 874-880.
McLaughlin VV, Channick R, Chin KM et al. Effect of selexipag on morbidity/mortality in pulmonary arterial hypertension: results of the GRIPHON Study. J Am Coll Cardiol, 2015; 65 (suppl. A): A380.
Humbert M, Barst RJ, Robbins IM et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J, 2004; 24: 353-359.
Galie N, Barbera JA, Frost A et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. New Engl J Med, 2015; 373: 834-844.
Paul GA, Gibbs JS, Boobis AR et al. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol, 2005; 60: 107-112.
Wrishko RE, Dingemanse J, Yu A et al. Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. J Clin Pharmacol, 2008; 48: 610-618.
Montani D, Bergot E, Günther S et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation, 2012; 125: 2128-2137.
Adir Y, Humbert M. Pulmonary hypertension in patients with chronic myeloproliferative disorders. Eur Respir J, 2010; 35: 1396-1406.
Lahm T, Chakinala MM. World Health Organization group 5 pulmonary hypertension. Clin Chest Med, 2013; 34: 753-778.
Toonkel RL, Borczuk AC, Pearson GD et al. Sarcoidosis associated fibrosing mediastinitis with resultant pulmonary hypertension: a case report and review of the literature. Respiration, 2010; 79: 341-345.
Le Pavec J, Lorillon G, Jaïs X et al. Pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension: clinical characteristics and impact of pulmonary arterial hypertension therapies. Chest, 2012; 142: 1150-1157.
Bogaard HJ, Al Husseini A, Farkas L et al. Severe pulmonary hypertension: the role of metabolic and endocrine disorders. Pulm Circ, 2012; 2: 148-154.
Pietra GG, Capron F, Stewart S et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol, 2004; 43 (suppl. 1): S25-S32.
Tuder RM, Abman SH, Braun T et al. Pulmonary circulation: development and pathology. J Am Coll Cardiol, 2009; 54 (suppl.): S3-S9.
Fedullo PF, Auger WR, Kerr KM, Rubin LJ. Chronic thromboembolic pulmonary hypertension. N Engl J Med, 2001; 345: 1465-1472.
Galiè N, Kim NHS. Pulmonary microvascular disease in chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc, 2006; 3: 571-576.
Dorfmüller P, Günther S, Ghigna MR et al. Microvascular disease in chronic thromboembolic pulmonary hypertension: a role for pulmonary veins and systemic vasculature. Eur Respir J, 2014; 44: 1275-1288.
Humbert M, Morrell NW, Archer SL et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol, 2004; 43 (suppl. 1): S13-S24.
Hassoun PM, Mouthon L, Barbera JA et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol, 2009; 54 (suppl.): S10-S19.
Morrell N, Adnot S, Archer S et al. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol, 2009; 54 (suppl.): S20-S31.
Delgado JF, Conde E, Sánchez V et al. Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure. Eur J Heart Fail, 2005; 7: 1011-1016.
Vachiery JL, Coghlan G. Screening for pulmonary arterial hypertension in systemic sclerosis. Eur Respir Rev, 2009; 18: 162-169.
Condliffe R, Kiely D, Peacock AJ et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med, 2009; 179: 91-92.
Galiè N, Palazzini M, Manes A. Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses. Eur Heart J, 2010; 31: 2080-2086.
Humbert M, Sitbon O, Chaouat A et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation, 2010; 122: 156-163.
Wald NJ. The definition of screening. J Med Screen, 2001; 8: 1.
Khanna D, Gladue H, Channick R et al. Recommendations for screening and detection of connective tissue disease associated pulmonary arterial hypertension. Arthritis Rheum, 2013; 65: 3194-3201.
Coghlan JG, Denton CP, Grünig E et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis, 2014; 73: 1340-1349.
Soubrier F, Chung WK, Machado R et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol, 2013; 62 (suppl.): D13-D21.
Krowka MJ, Swanson KL, Frantz RP et al. Portopulmonary hypertension: results from a 10-year screening algorithm. Hepatology, 2006; 44: 1502-1510.
Steen V, Medsger TA. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum, 2003; 48: 516-522.
Schreiber BE, Valerio CJ, Keir GJ et al. Improving the detection of pulmonary hypertension in systemic sclerosis using pulmonary function tests. Arthritis Rheum, 2011; 63: 3531-3539.
Williams MH, Handler CE, Akram R et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J, 2006; 27: 1485-1494.
Cavagna L, Caporali R, Klersy C et al. Comparison of brain natriuretic peptide (BNP) and NT-proBNP in screening for pulmonary arterial hypertension in patients with systemic sclerosis. J Rheumatol, 2010; 37: 2064-2070.
Allanore Y, Borderie D, Avouac J et al. High N-terminal probrain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum, 2008; 58: 284-291.
Valerio CJ, Schreiber BE, Handler CE et al. Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension. Arthritis Rheum, 2013; 65: 1074-1084.
Hachulla E, Gressin V, Guillevin L et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum, 2005; 52: 3792-3800.
Alkotob ML, Soltani P, Sheatt MA et al. Reduced exercise capacity and stress-induced pulmonary hypertension in patients with scleroderma. Chest, 2006; 130: 176-181.
Huez S, Roufosse F, Vachiery JL et al. Isolated right ventricular dysfunction in systemic sclerosis: latent pulmonary hypertension? Eur Respir J, 2007; 30: 928-936.
Grunig E, Weissmann S, Ehlken N et al. Stress Doppler echocardiography in relatives of patients with idiopathic and familial pulmonary arterial hypertension: results of a multicenter European analysis of pulmonary artery pressure response to exercise and hypoxia. Circulation, 2009; 119: 1747-1757.
D'Alto M, Ghio S, D'Andrea A et al. Inappropriate exercise-induced increase in pulmonary artery pressure in patients with systemic sclerosis. Heart,2011; 97: 112-117.
Pavelescu A, Vanderpool R, Vachiery JL et al. Echocardiography of pulmonary vascular function in asymptomatic carriers of BMPR2 mutations. Eur Respir J, 2012; 40: 1287-1289.
Hachulla E, Carpentier P, Gressin V et al. Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinerAIR-Sclerodermie study. Rheumatology, 2009; 48: 304-308.
Gladwin MT, Sachdev V, Jison ML et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med, 2004; 350: 886-895.
Parent F, Bachir D, Inamo J et al. A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med, 2011; 365: 44-53.
Fonseca GHH, Souza R, Salemi VMC et al. Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease. Eur Respir J, 2012; 39: 112-118.
Larkin EK, Newman JH, Austin ED et al. Longitudinal analysis casts doubt on the presence of genetic anticipation in heritable pulmonary arterial hypertension. Am J Respir Crit Care Med, 2012; 186: 892-896.
Colle IO, Moreau R, Godinho E et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology, 2003; 37: 401-409.
Humbert M, Yaici A, de Groote P et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum, 2011; 63: 3522-3530.
Castro M, Krowka MJ, Schroeder DR et al. Frequency and clinical implications of increased pulmonary artery pressures in liver transplant patients. Mayo Clin Proc, 1996; 71: 543-551.
Hachulla E, de Groote P, Gressin V et al. The 3-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study (ItinérAIR-Sclérodermie Study). Arthritis Rheum, 2009; 60: 1831-1839.
Matura LA, McDonough A, Carroll DL. Health-related quality of life and psychological states in patients with pulmonary arterial hypertension. J Cardiovasc Nurs, 2014; 29: 178-184.
Fernandes CJ, Martins BC, Jardim CV et al. Quality of life as a prognostic marker in pulmonary arterial hypertension. Health Qual Life Outcomes, 2014; 12: 130.
Rubenfire M, Lippo G, Bodini BD et al. Evaluating health-related quality of life, work ability, and disability in pulmonary arterial hypertension: an unmet need. Chest, 2009; 136: 597-603.
McKenna S, Doughty N, Meads D et al. The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension. Qual Life Res, 2006; 15: 103-115.
Cima K, Twiss J, Speich R et al. The German adaptation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR). Health Qual Life Outcomes, 2012; 10: 110.
Swetz KM, Shanafelt TD, Drozdowicz LB et al. Symptom burden, quality of life, and attitudes toward palliative care in patients with pulmonary arterial hypertension: results from a cross-sectional patient survey. J Heart Lung Transplant, 2012; 31: 1102-1108.
Yorke J, Corris P, Gaine S et al. emPHasis-10: development of a health-related quality of life measure in pulmonary hypertension. Eur Respir J, 2014; 43: 1106-1113.
Cenedese E, Speich R, Dorschner L et al. Measurement of quality of life in pulmonary hypertension and its significance. Eur Respir J, 2006; 28: 808-815.
Zlupko M, Harhay MO, Gallop R et al. Evaluation of disease-specific health-related quality of life in patients with pulmonary arterial hypertension. Respir Med, 2008; 102: 1431-1438.
Matura LA, McDonough A, Hanlon AL, Carroll DL. Development and initial psychometric properties of the Pulmonary Arterial Hypertension Symptom Scale (PAHSS). Appl Nurs Res, 2015; 28: 42-47.
